Catalyst Pharmaceuticals (CPRX)

Executive Summary

Catalyst Pharmaceuticals is a profitable commercial-stage biopharmaceutical company specializing in rare neuromuscular and neurological diseases. Its lead product, Firdapse (amifampridine phosphate), is approved for Lambert-Eaton myasthenic syndrome (LEMS) and generates consistent revenue. The company is leveraging its specialized commercial platform and regulatory expertise to expand into additional indications, including congenital myasthenic syndrome (CMS) and spinal muscular atrophy (SMA). With a strong balance sheet and a focus on orphan drug development, Catalyst is well-positioned for sustainable growth. Key upcoming milestones include potential label expansions and pipeline advancement, which could drive further value.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on sNDA for Firdapse in Congenital Myasthenic Syndrome80% success
• Q4 2026Initiation of Phase 3 trial for amifampridine in Spinal Muscular Atrophy70% success
• H2 2026Potential partnership or acquisition of pipeline asset (e.g., CPP-109 or new indication)40% success